Isabela Domínguez Fernández
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Isabela Domínguez Fernández has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Annarli Olivia Rodriguez Ferreiro
Department of Pharmacy, Universidad de Oriente, Santiago de Cuba, Cuba, Cuba
1 shared publication - Clara Azalea Berenguer Rivas
Department of Pharmacy, Universidad de Oriente, Santiago de Cuba, Cuba, Cuba
1 shared publication - Félix Jesús Labañino Roldo
Empresa de farmacias y Óptica, Provincia Guantánamo, Cuba
1 shared publication - Silvia del Carmen Molina Bertrán
Universidad de La Habana
1 shared publication
Latest Publications
- Open Access
- 11 May 2024
- Published by Editorial Primmate in Orange Journal
- Vol. 6 (11) , 33-42
Pharmacovigilance of carbamazepine in the treatment of Central Nervous System conditions
Anticonvulsants are crucial for treating neurological diseases, necessitating close pharmacovigilance due to their potential risks. For this reason, a prospective descriptive study was conducted to characterize drug-related adverse reactions associated with the use of carbamazepine in the health area of the "Ramon Lopez Peña" Polyclinic, covering the period from July to December 2022. The sample consisted of 35 patients, characterized based on demographic, clinical, and pharmacotherapeutic variables. The detected drug-related adverse events were classified according to causality, severity, and frequency of occurrence. The results showed that the age group of 40-75 years (45.7%) predominated, along with female gender, mixed ethnicity, pre-university education level, and 54.2% did not have any unhealthy habits. The most common diagnosis was epilepsy (68.4%) and among the associated diseases, hypertension was prevalent. The most consumed medications were captopril, hydrochlorothiazide, paracetamol, and metamizole (dipirona). Drug interactions were detected, and 73 adverse reactions occurred, with the nervous system being the most affected at 56.0%. Possible adverse reactions (42.5%), frequent (49.4%), and mild (58.9%) predominated. This study underscores the importance of continuous and effective monitoring in pharmacovigilance to enhance patient safety under carbamazepine treatment, thereby promoting a more rational use of this medication.
- 11 May 2024
- Published by Editorial Primmate in Orange Journal
- Vol. 6 (11) , 33-42
Open AccessPharmacovigilance of carbamazepine in the treatment of Central Nervous System conditions
Anticonvulsants are crucial for treating neurological diseases, necessitating close pharmacovigilance due to their potential risks. For this reason, a prospective descriptive study was conducted to characterize drug-related adverse reactions associated with the use of carbamazepine in the health area of the "Ramon Lopez Peña" Polyclinic, covering the period from July to December 2022. The sample consisted of 35 patients, characterized based on demographic, clinical, and pharmacotherapeutic variables. The detected drug-related adverse events were classified according to causality, severity, and frequency of occurrence. The results showed that the age group of 40-75 years (45.7%) predominated, along with female gender, mixed ethnicity, pre-university education level, and 54.2% did not have any unhealthy habits. The most common diagnosis was epilepsy (68.4%) and among the associated diseases, hypertension was prevalent. The most consumed medications were captopril, hydrochlorothiazide, paracetamol, and metamizole (dipirona). Drug interactions were detected, and 73 adverse reactions occurred, with the nervous system being the most affected at 56.0%. Possible adverse reactions (42.5%), frequent (49.4%), and mild (58.9%) predominated. This study underscores the importance of continuous and effective monitoring in pharmacovigilance to enhance patient safety under carbamazepine treatment, thereby promoting a more rational use of this medication.